Our achievements. Our accomplishments. Our impact.



  • Stem Cell Genomics

    SCN’s Gene Expression Project was made possible through the Network’s collaborative approach to research, and the Project’s use of a single centre to undertake a standardized analysis of hundreds of stem cell lines allowed for the creation of pertinent data and meta-data to be accessed by thousands of researchers around the world.

    READ STORY

  • Till & McCulloch Meetings

    The Stem Cell Network’s Annual General Meeting, which metamorphosed into the Till & McCulloch Meetings, is a one-of-a-kind venue for trainees and young scientists to network and gain experience in the competitive field of regenerative medicine.

    READ STORY

  • Ethical, Legal and Social Issues

    SCN established and funded a world-leading arms-length research program to examine the key social, legal and ethical implications of stem cell research and, based upon this credible and research-based evidence, has provided critical policy recommendations to government that have impacted not only how research is conducted in Canada, but how Canadians will access potential therapies in the future.

    READ STORY

  • Commercialization

    The Stem Cell Network’s catalysis of commercialization of stem cell research has led to 399 patent applications, 60 issued patents, 43 licenses granted, the growth or launch of 11 start-up biotechnology companies and the establishment of a new Centre for the Commercialization of Regenerative Medicine (CCRM) to develop a strong industry presence in several emerging technology areas likely to be crucial to the future delivery of stem cell-based therapies.

    READ STORY

  • Patient Engagement

    The Stem Cell Network engaged world-leading researchers and ethicists to provide Canadians with credible and accessible information on the latest advancements in stem cell research.

    READ STORY

  • Clinical Trials

    When the Stem Cell Network was first funded, its leadership considered that catalyzing a single clinical trial during its 14-year mandate would have been a success. Instead, the Network’s research investments have led to 12 clinical trials on various diseases, with even more in the development pipeline.

    READ STORY